Download this Press Release as a PDF
Oxford, UK – 10th February 2025 – IngenOx Therapeutics, the Oxford-based biopharmaceutical company, announced
that its Chief Medical Officer, Professor David Kerr CBE, met with Chinese Premier Li Qiang on 26 January 2025 at an
international symposium held at the Great Hall of the People in Beijing. The discussion focused on new initiatives to tackle
the global socio-economic burden of cancer.
Professor Kerr, who received the 2024 Chinese Government Friendship Award, was joined by a distinguished panel of
international experts from various fields to explore how technological innovation can deliver tangible benefits for people
worldwide.
Professor David Kerr and Premier Li Qiang at the Great Hall of the People, Beijing
During his presentation, Professor Kerr highlighted the significant progress already achieved through UK-China
academic partnerships in cancer prevention, research, and treatment. A key example is the Sichuan University (West
China Hospital)-Oxford University Gastrointestinal Cancer Centre (https://www.cancer.ox.ac.uk/research/networks/
west-china-hospital), which is dedicated to developing and implementing effective cancer control strategies.
To further build on these advancements, Professor Kerr proposed the establishment of a “China-UK Cancer Prevention
and Control Alliance.” This initiative would bring together leading healthcare, research, and policy experts from both
nations to share best practices, develop innovative cancer control models, and drive major breakthroughs in cancer
prevention, treatment, and healthcare systems.
David Kerr, CMO of IngenOx Therapeutics and Professor of Cancer Medicine at the University of Oxford, commented:
“It was a great honour to be asked to participate in this symposium led by Premier Li. I firmly believe that international
collaboration, bringing together some of the greatest cancer scientists and clinicians in the world, is the optimal way for the
UK and China to cooperate to best serve the community of cancer patients we represent.”
Nick La Thangue, CEO of IngenOx Therapeutics and Professor of Cancer Biology at the University of Oxford, commented:
“We are excited about David’s proposals to initiate new partnerships with world renowned cancer centres. IngenOx is ideally
positioned to assist in achieving these important objectives.”
NOTES:
About David Kerr
Professor David Kerr CBE MD DSc FRCP FRGCP FACP FESMO FMedSci is a British medical oncologist with over 40 years of
experience in cancer research. His primary interest is the treatment and management of bowel cancer. He is currently
Professor of Cancer Medicine at the University of Oxford and holds additional positions as Honorary Consultant Medical
Oncologist at the Oxford Cancer Centre, Co-Director of the Oxford-Sichuan Gastrointestinal Cancer Centre, and Honorary
Professor at the University of Oslo. In the business field, David has co-founded several companies, including Cobra Therapeutics,
Oxford Cancer Biomarkers, Celleron Therapeutics, SynOx Therapeutics, and IngenOx Therapeutics.
About IngenOx Therapeutics
is a biopharmaceutical company focused on delivering new precision medicine drugs and vaccines to treat the most
difficult cancers, often referred to as cold tumours. It is a spinout from the University of Oxford and is located in the
Oxford Science Park, UK. Its pipeline comprises early to late-stage products that work in different ways to activate the
immune response against cold tumours, which are generally poorly recognised by the immune system. An exciting
proprietary platform technology focuses on precision cancer vaccines that act by targeting the immune response to a
novel source of cancer antigens.
The company has secured multiple rounds of investment and has numerous license and partnership agreements in place.
For more information see www.ingenox.com